Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1 | BiotechTV - News | Podwise
Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
BiotechTV - News - Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
Sign in to continue reading, translating and more.
